List view / Grid view
22 August 2005 | By Gilbert S. Omenn, M.D.,Ph.D University of Michigan
Less than a week after Nature and Science published the special issues on the ’blueprint‘ for the human genome sequence 15-16 Feb, 2001, the Financial Times of 21 February, 2001, ran a major article about proteomics, calling proteins “the real stuff of life”. Proteins are, indeed, the effector molecules for…
22 August 2005 | By José M Mato, Isabel Pérez-Mato, Félix Elortza, CIC bioGUNE and Julio Font, Noray Bioinformatics, S.L
The availability of the complete sequence of some model organism genomes, including the human genome, offers new opportunities for biological research. The goal is to establish technology to identify all the proteins involved in a particular biological process and the interactions between them.
22 August 2005 | By Erwin Adams, Ann Van Schepdael and Jos Hoogmartens, Laboratory for Pharmaceutical Chemistry and Drug Analysis, Catholic University of Leuven, Belgium
The European Pharmacopoeia (Ph. Eur.)1 monographs are subject to regular adaptation in order to cope with progressing quality requirements. This contribution outlines the evolution in analytical requirements and techniques in monographs for organic substances. These monographs generally carry the subheadings definition, characters, identification, tests, assay and impurities.
22 August 2005 | By Dr Dalin Nie, Associate Director, and Deborah S. Hartman, Director, Lead Discovery, AstraZeneca Pharmaceuticals, Wilmington
Compound management is an emerging discipline that represents a core component of the drug discovery process, from early phases involving high throughput screening (HTS) to late-stage lead optimisation screening cascades.
22 August 2005 | By Thomas Keller, MPhil, PhD, Head of Applied Technology Group UK, European & International Operations, GlaxoSmithKline R&D
The most important factors for ensuring a successful future are innovation and an effective governance structure. Within this model1 in the pharmaceutical industry, the introduction of new technology is one of the key factors. This provides an organisation with efficient and reliable systems to facilitate the incorporation of new scientific…
22 August 2005 | By Stefan Prechtl, Group Leader, High Content Analysis and Philip Denner, Schering AG
High-Content Analysis (HCA) provides a drug discovery tool capable of rapid screening of drug effects in pharmacologically relevant cell culture systems. Interest in HCA has been increasing during the past few years. This reflects the confidence that HCA-technology has established due to the stability and reliability offered to the drug…
22 August 2005 | By James Herrington and Owen B. McManus, Department of Ion Channels, Laszlo Kiss, Pain Research, Merck Research Laboratories
Ion channels are membrane spanning proteins with narrow hydrophilic pores that support the passive flux of inorganic ions across the cell membrane.
22 August 2005 | By Marleen de Veij, Dr. Peter Vandenabeele and Prof. Dr. Luc Moens, Laboratory of Analytical Chemistry, Ghent University
Traditionally, analyses in pharmaceutical research and industry were often performed using Nuclear Magnetic Resonance (NMR) or Mass Spectrometry (MS). However, researchers are aware that Raman Spectroscopy possesses advantageous characteristics for the pharmaceutical world.
22 August 2005 | By Joep Timmermans, Ph.D., Senior Manager/Team Leader, Process Analytical Support Group – Americas Implementation Team, Pfizer Global Manufacturing
While the current attention and focus on Process Analytical Technologies (PAT) may make you believe otherwise, PAT measurement systems have been used in the pharmaceutical industry, Pfizer included, for some time, albeit often to a limited extent.
22 August 2005 | By Dr Hans H. Schicht, Dr. sc. techn., Dr. Hans Schicht Ltd. Contamination Control Consulting
Regulatory guidance documents, such as Annex 1 to the GMP guideline of the European Union1 and FDA's comparable Guidance for Industry2 establish the objectives to be met by pharmaceutical contamination control systems – especially those for the production of sterile medicinal drugs.
22 August 2005 | By Michel Philippart, Director, Sourcing & Procurement, GlaxoSmithKline Biologicals s.a.
In today’s challenging environment, aggressive cost control has become a common theme in the pharmaceutical industry.
22 August 2005 | By Professor Naomi E. Chayen, Biological Structure and Function Section, Division of Biomedical Sciences, Imperial College London
We are currently living in an exciting age, where for the fist time ever, human diseases are being understood at a molecular level. Protein crystallography plays a major role in this understanding because proteins, being the major machinery of living things, are often the targets for drugs.
22 August 2005 | By Dr Johannes Ottl, Laboratory Head, Novartis Pharmaceuticals
The pharmaceutical industry continues to face an ever-changing, increasingly competitive business environment. This makes it imperative for drug discovery and development efforts to incorporate new technologies in order to reduce time-to-market to survive in today’s competitive marketplace. This industry pressure to shorten the R&D process has seen high-throughput screening (HTS)…
20 May 2005 | By Jeroen DeGroot, PhD; Anne-Marie Zuurmond, PhD, Daniel Eefting, MD; Ruud A Bank, PhD; and Paul Quax, PhD.; TNO Quality of Life, Business Unit Biomedical Research
All diseases have a genetic component, whether inherited or resulting from the body's response to environmental stresses such as viruses, toxins or trauma. The successes of the human genome project have enabled researchers to pinpoint errors in genes that cause or contribute to disease.
20 May 2005 | By William Carley, Ph.D., Experimental Medicine, Pfizer Global R&D
Biomarker application during drug development is driven by the need to define disease and therapeutic efficacy/safety earlier, better and with reduced cost.
